IL-17A in diabetic kidney disease: protection or damage.
Int Immunopharmacol
; 108: 108707, 2022 Jul.
Article
em En
| MEDLINE
| ID: mdl-35344813
ABSTRACT
The effect of IL-17A in diabetic kidney disease (DKD) has received increasing attention. Interleukin (IL)-17A promotes renal inflammation and the progression of DKD, and IL-17A deficiency improves experimental DKD. However, recent studies have found that the effect of IL-17A on DKD is more complicated than the negative impact. IL-17A alleviates renal inflammation and fibrosis via regulating autophagy or the macrophage phenotype. Moreover, paradoxical expression of IL-17A has been reported in human DKD. This review focuses on how IL-17A affects the progression of DKD and the resulting opportunities and challenges.
Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Interleucina-17
/
Diabetes Mellitus
/
Nefropatias Diabéticas
Limite:
Humans
Idioma:
En
Ano de publicação:
2022
Tipo de documento:
Article